Literature DB >> 9819792

Homing behaviour of the malignant cell clone in multiple myeloma.

I Van Riet1, K Vanderkerken, C de Greef, B Van Camp.   

Abstract

Multiple myeloma (MM) represents a B cell malignancy characterised by the presence of a monoclonal population of end-stage B cells in the bone marrow. Although fully matured bone marrow plasma cells are the predominant cell type in MM, there is much evidence that also more immature B cells are included in the malignant cell clone which are considered to be the myeloma precursor cells. The fact that these cells are detectable in the blood circulation and that their number increases with disease progression, makes it very likely that they represent the component of the tumour clone that mediates disease dissemination. This implies that these cells must have the potential to extravasate and home to the bone marrow environment. Like the migration mechanisms used by normal leukocytes and/or metastatic tumour cells of non-haematopoietic origin, it can be assumed that this bone marrow homing process is mediated by adhesive interactions and chemotactic signals provided by the microenvironment of the tumour. Once in the bone marrow compartment, myeloma cells will receive the appropriate signals to grow and survive. This aspect of tumour-homing is found to be the result of a functional interplay between the myeloma cells and the surrounding microenvironment, involving the action of several cytokines and adhesion molecules. In the end phase of the disease, myeloma cells can lose their stroma-dependency resulting in extramedullary tumour growth. We review normal B cell homing and discuss molecular mechanisms that determine the homing behaviour of the malignant cell clone in MM.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9819792     DOI: 10.1007/BF02821934

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  76 in total

Review 1.  Regulation of human B-cell ontogeny.

Authors:  F M Uckun
Journal:  Blood       Date:  1990-11-15       Impact factor: 22.113

Review 2.  Cadherins: a molecular family important in selective cell-cell adhesion.

Authors:  M Takeichi
Journal:  Annu Rev Biochem       Date:  1990       Impact factor: 23.643

Review 3.  Antigen-driven selection of virgin and memory B cells.

Authors:  I C MacLennan; D Gray
Journal:  Immunol Rev       Date:  1986-06       Impact factor: 12.988

Review 4.  Integrins: a family of cell surface receptors.

Authors:  R O Hynes
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

5.  Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma.

Authors:  X G Zhang; B Klein; R Bataille
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

6.  Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias.

Authors:  P Corradini; M Ladetto; C Voena; A Palumbo; G Inghirami; D M Knowles; M Boccadoro; A Pileri
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

Review 7.  Germinal centers.

Authors:  I C MacLennan
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

8.  Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization.

Authors:  C Pellat-Deceunynck; S Barillé; D Puthier; M J Rapp; J L Harousseau; R Bataille; M Amiot
Journal:  Cancer Res       Date:  1995-08-15       Impact factor: 12.701

9.  Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs.

Authors:  C Hannum; J Culpepper; D Campbell; T McClanahan; S Zurawski; J F Bazan; R Kastelein; S Hudak; J Wagner; J Mattson
Journal:  Nature       Date:  1994-04-14       Impact factor: 49.962

10.  Extensive extramedullary disease in myeloma. An uncommon variant with features of poor prognosis and dedifferentiation.

Authors:  S M Sanal; M Yaylaci; K A Mangold; C G Pantazis
Journal:  Cancer       Date:  1996-04-01       Impact factor: 6.860

View more
  10 in total

1.  beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium.

Authors:  Valerie M Weaver; Sophie Lelièvre; Johnathon N Lakins; Micah A Chrenek; Jonathan C R Jones; Filippo Giancotti; Zena Werb; Mina J Bissell
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

Review 2.  Microarray-based understanding of normal and malignant plasma cells.

Authors:  John De Vos; Dirk Hose; Thierry Rème; Karin Tarte; Jérôme Moreaux; Karéne Mahtouk; Michel Jourdan; Hartmut Goldschmidt; Jean-François Rossi; Friedrich W Cremer; Bernard Klein
Journal:  Immunol Rev       Date:  2006-04       Impact factor: 12.988

Review 3.  Extramedullary multiple myeloma.

Authors:  Manisha Bhutani; David M Foureau; Shebli Atrash; Peter M Voorhees; Saad Z Usmani
Journal:  Leukemia       Date:  2019-11-27       Impact factor: 11.528

Review 4.  Adhesion molecules in multiple myeloma oncogenesis and targeted therapy.

Authors:  Maroun Bou Zerdan; Lewis Nasr; Joseph Kassab; Ludovic Saba; Myriam Ghossein; Marita Yaghi; Barbara Dominguez; Chakra P Chaulagain
Journal:  Int J Hematol Oncol       Date:  2022-04-26

Review 5.  Extravasation and homing mechanisms in multiple myeloma.

Authors:  Isabelle Vande Broek; Karin Vanderkerken; Benjamin Van Camp; Ivan Van Riet
Journal:  Clin Exp Metastasis       Date:  2007-10-19       Impact factor: 5.150

6.  Laminin-1-induced migration of multiple myeloma cells involves the high-affinity 67 kD laminin receptor.

Authors:  I Vande Broek; K Vanderkerken; C De Greef; K Asosingh; N Straetmans; B Van Camp; I Van Riet
Journal:  Br J Cancer       Date:  2001-11-02       Impact factor: 7.640

7.  Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse.

Authors:  K Vanderkerken; C De Greef; K Asosingh; B Arteta; M De Veerman; I Vande Broek; I Van Riet; M Kobayashi; B Smedsrod; B Van Camp
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

8.  Non-invasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma.

Authors:  Simone S Riedel; Anja Mottok; Christian Brede; Carina A Bäuerlein; Ana-Laura Jordán Garrote; Miriam Ritz; Katharina Mattenheimer; Andreas Rosenwald; Hermann Einsele; Bjarne Bogen; Andreas Beilhack
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

9.  Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma.

Authors:  H W Woitge; M Pecherstorfer; E Horn; A V Keck; I J Diel; P Bayer; H Ludwig; R Ziegler; M J Seibel
Journal:  Br J Cancer       Date:  2001-02-02       Impact factor: 7.640

10.  Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3.

Authors:  I Vande Broek; K Asosingh; K Vanderkerken; N Straetmans; B Van Camp; I Van Riet
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.